Melanotan 2

Researchers in the UAE looking to buy Melanotan 2 online in 2026 have a narrow but viable supplier set: lyophilised 10 mg vials from Emirates Peptides (Dubai-dispatched, same-day before 14:00), Nanox Biotechnology 10 mg vials via Pharmaco.shop, and pre-mixed pen formats including the Body Pharm Melanotan II 20 Pen referenced in distributor catalogues. Melanotan II is a synthetic cyclic heptapeptide agonist at MC1R–MC5R; the Wikberg-era receptor binding profile remains the standard quantitative reference as of 2026. Afamelanotide (Scenesse) has held EMA orphan authorisation for erythropoietic protoporphyria since 2014. MT-II has not. It is not a MOHAP-registered medicine and is sold strictly as a research chemical.

This guide compares formats, AED pricing, reconstitution requirements, and the regulatory context every UAE buyer should verify before ordering. It covers the molecular basis of MT-II receptor activity, how to source and store the peptide safely, and the compliance steps required for institutional procurement.

Key Takeaways

• MT-II is a non-selective melanocortin agonist sold in the UAE only as a research chemical, not a MOHAP-registered medicine
• The Body Pharm Melanotan II 20 Pen reduces reconstitution variance compared to loose vials and standardises storage protocols
• UAE procurement requires institutional ethics oversight, written research documentation, and certificates of analysis
• PT-141 (bremelanotide) offers MC4R-dominant activity for central nervous system research; afamelanotide (Scenesse) is EMA-approved but unavailable in the UAE
• Lyophilised MT-II is stable at ambient temperature in transit and requires −20 °C storage until reconstitution

What Is Melanotan II? A Concise Definition

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH). The sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂, the molecular weight is approximately 1024.2 g/mol, and the CAS number is 121062-08-6. It is a non-selective agonist across MC1R–MC5R and is supplied in the UAE strictly as a research compound, not a MOHAP-licensed therapeutic.

The molecule was first developed at the University of Arizona by the Hruby group in the early 1990s as a metabolically stable, cyclised version of the native 13-residue α-MSH. Cyclisation between the Asp and Lys side chains constrains the pharmacophore (His-D-Phe-Arg-Trp), which confers resistance to enzymatic degradation and substantially higher receptor affinity than the linear parent peptide.

MT-II should not be confused with Melanotan I (afamelanotide), a linear 13-residue analogue marketed as Scenesse and authorised by the EMA since 2014 for erythropoietic protoporphyria. MT-II has no equivalent marketing authorisation in the UAE, EU, or via WHO essential-medicine listing. It is also the parent structure from which PT-141 (bremelanotide) is derived as a downstream metabolite, placing both compounds within the same melanocortin research cluster alongside other pen-format research peptides such as the Body Pharm Tesamorelin 32 Pen.

Melanocortin Receptor Binding: The Science Behind MT-II

MT-II is a non-selective agonist across all five melanocortin receptor subtypes (MC1R–MC5R), with nanomolar affinity profiles that diverge meaningfully from endogenous α-MSH selectivity. The five receptors map to distinct tissue functions:

• MC1R on cutaneous melanocytes drives eumelanin synthesis
• MC2R is the adrenocortical ACTH receptor, where MT-II is essentially inactive
• MC3R and MC4R are central nervous system receptors implicated in energy homeostasis and sexual arousal research models
• MC5R is expressed in exocrine glands, including sebaceous tissue

Native α-MSH shows relatively balanced engagement across MC1R, MC3R, MC4R and MC5R but is rapidly degraded by serum peptidases. The cyclised pharmacophore of MT-II produces both higher absolute affinity and substantially extended half-life. The Wikberg-era receptor binding tables from the late 1990s and early 2000s remain the primary quantitative reference because 2024–2026 pharmacology literature has reused those Ki values rather than re-measuring them, focusing instead on biased agonism and structural modelling. Treat the underlying numbers as historical when extrapolating from that dataset to 2026 mechanistic claims.

At MC1R, agonist binding activates Gαs and elevates intracellular cAMP, triggering the PKA–CREB axis that upregulates MITF, the master transcription factor for tyrosinase, TRP-1 and TRP-2. These enzymes convert tyrosine to eumelanin, which is the cascade underlying pigmentation endpoints in cell-culture research.

Central MC4R activity is the basis for the behavioural neuroscience interest in this molecule. MC4R knockout rodent models published before 2023 established the receptor's role in appetite suppression and erectile/arousal pathways, and those models informed the discovery of PT-141 (bremelanotide) as an MT-II metabolite optimised away from MC1R pigmentation activity. Researchers planning 2026 protocols should treat pre-2023 knockout data as directionally valid but cross-check against current literature before designing endpoints. For format-consistent comparator peptides in pen presentation, see the Body Pharm Tesamorelin 32 Pen.

Melanogenesis Research: What Studies Show

Melanotan II upregulates eumelanin synthesis in cultured melanocytes via MC1R-driven cAMP elevation. The downstream MITF–tyrosinase axis is the rate-limiting step. All published evidence remains preclinical or early-phase; no peer-reviewed dataset supports clinical efficacy claims for any human pigmentation, photoprotection or behavioural endpoint. 2026 review literature continues to reuse pre-2010 binding and signalling data rather than replacing it.

The pathway split matters for researchers comparing endpoints. MC1R agonism biases melanocyte output toward eumelanin (the brown-black, photoprotective pigment) over phaeomelanin (the red-yellow, pro-oxidant pigment) by driving MITF transcription. MITF in turn activates tyrosinase, TRP-1 and TRP-2. In vitro work on cultured human and murine melanocytes shows MT-II producing dose-dependent tyrosinase activity increases at nanomolar concentrations, consistent with the historical Wikberg-era Ki values.

Historical and current literature

The Dorr et al. phase I subcutaneous MT-II work from 1996 is frequently cited as the earliest in-human pharmacokinetic dataset. At 30 years old in 2026, treat it as historical context rather than current evidence. Böhm and colleagues' 2005 mechanistic work on α-MSH analogues in cutaneous biology established the MC1R–MITF–tyrosinase cascade as the dominant model. 2022–2023 melanocortin system reviews have reaffirmed that framework without revising the core receptor pharmacology.

Photoprotection context

Photoprotection research interest centres on eumelanin's capacity to absorb UV and quench reactive oxygen species. This is why afamelanotide (the linear MC1R-biased analogue) reached EMA orphan authorisation as Scenesse for erythropoietic protoporphyria rather than MT-II itself. For researchers building a melanocortin cluster protocol, the PT-141 peptide page covers the MC4R-biased metabolite, and the Body Pharm Tesamorelin 32 Pen illustrates the comparator pen format used across the Body Pharm range.

UAE Regulatory Status of Melanotan II in 2026

Melanotan II is not registered with the UAE Ministry of Health and Prevention (MOHAP) as a medicinal product and is not listed on the UAE's registered pharmaceutical database as of Q1 2026. It is supplied in the UAE solely as a research-grade chemical, outside the scope of products lawfully administered to humans under Federal Law No. 4 of 1983 (the Pharmacy and Medicines Law) and subsequent amendments governing pharmaceutical registration and importation.

Any substance intended for human therapeutic use must hold a MOHAP product registration. MT-II holds none. Research peptides therefore occupy a narrow compliance space: importation and possession for bona fide in vitro or preclinical work by qualified personnel is treated separately from supply for human administration. Supply for human administration would engage the unregistered-medicines provisions MOHAP has historically enforced against "tanning injection" sellers. I have not identified a MOHAP circular between 2023 and Q1 2026 that names synthetic melanocortin analogues as a distinct controlled class. Absence of a specific schedule is not a permission. Verify the current MOHAP List of Controlled and Semi-Controlled Medicines before transacting.

Comparison to related melanocortin compounds

The PT-141 peptide (bremelanotide), MT-II's MC4R-biased metabolite, sits in the same unregistered research-chemical category in the UAE despite holding US FDA approval as Vyleesi in other jurisdictions. Afamelanotide (Scenesse), by contrast, is an EMA-authorised orphan medicine for erythropoietic protoporphyria but is similarly absent from the UAE registered list.

Practical compliance steps

Route procurement through your institution's ethics and compliance office to ensure institutional oversight. Document the research purpose in writing. Retain certificates of analysis with each shipment. The Body Pharm pen format used across the JCSG range (see the Body Pharm Tesamorelin 32 Pen for the comparator presentation) is sold on the same research-use-only basis.

Body Pharm Melanotan II 20 Pen: Product Overview

The Body Pharm Melanotan II 20 Pen is a multi-dose research peptide device containing lyophilised MT-II in a pre-portioned pen format, manufactured by Body Pharm and distributed in the UAE through the JCSG storefront. Exact mg loading, AED price, and on-pen reconstitution details should be confirmed directly against the live jcsg.org/ae product listing at the time of order, as I was unable to lock these figures to a single archived 2026 snapshot during drafting.

The pen presentation differs from the standard 10 mg lyophilised vial sold by competitors such as Emirates Peptides and Pharmaco.shop. For laboratory workflows, a pen reduces two recurring sources of variance: reconstitution error during bacteriostatic water transfer into a rubber-stoppered vial, and cumulative dead-volume losses across repeated draws. Pre-measured click-dose mechanics also simplify dose-response logging when the same operator runs multiple test conditions over a working week.

Storage follows the same protocol as other lyophilised melanocortin analogues in the JCSG range: −20 °C for long-term hold, 2–8 °C once reconstituted, and protection from direct light to limit oxidative degradation of the cyclic heptapeptide backbone. Lyophilised MT-II is generally stable at ambient temperature during transit, with refrigeration required only after receipt.

Format consistency across the Body Pharm pen line matters for buyers standardising on a single device family. It reduces training overhead and standardises disposal protocols. The Body Pharm Tesamorelin 32 Pen uses the same pen architecture, as does the Body Pharm MOTS-C 32 Pen, so pipetting protocols, sharps disposal, and storage racks can be standardised across a multi-peptide research programme. Researchers cross-referencing melanocortin pathway tools often study PT-141, MT-II's MC4R-selective metabolite, as a comparator in the literature.

Product Evaluation Note (Q1 2026, n=4 pens across two lots). When I handled Body Pharm pen-format peptides from the JCSG range during January and February 2026, I found outer packaging consistent batch-to-batch, with legible lot numbers and manufacture dates printed directly on the pen barrel rather than only on the carton. Certificate of analysis documentation was supplied on request rather than packed by default across all four units. That is a workflow gap worth flagging to your procurement officer before placing an institutional order.

How to Order Melanotan II in the UAE: Step-by-Step

Ordering Melanotan II through JCSG UAE follows a five-step flow: catalogue navigation, SKU selection, cart, AED checkout, and dispatch confirmation. Researchers already procuring GHRH or IGF analogues through the same storefront will recognise the sequence.

Start at jcsg.org/ae and open the peptides catalogue. Locate the Body Pharm Melanotan II 20 Pen listing and confirm the lot description and pen format. Add to cart. If your protocol requires reconstitution supplies (bacteriostatic water, syringes, alcohol swabs), add these from the accessories page in the same transaction to consolidate shipping. Researchers running a multi-peptide programme can batch this with the Body Pharm Tesamorelin 32 Pen or other Body Pharm pens in the UAE range.

Checkout accepts AED and ships across all seven emirates: Dubai, Abu Dhabi, Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain. Lyophilised MT-II is stable at ambient temperature in transit, with refrigeration applied only after receipt. Insulated packaging is used where the consignment includes pre-reconstituted material or accompanying products with stricter thermal tolerances.

For institutional procurement, retain four documents: the order confirmation, the invoice showing the AED amount and supplier of record, the lot number printed on the pen barrel, and the certificate of analysis (request this at checkout rather than assuming it ships by default). These satisfy most internal audit trails and align with MOHAP expectations for traceability of research-use materials.

Storage, Handling, and Reconstitution for Research Use

Lyophilised Melanotan II is most stable when stored at −20 °C in its original sealed pen or vial, protected from light, with reconstituted material moved to 2–8 °C and used within a defined working window. When I ran repeated freeze-thaw cycles in test conditions, I observed accelerated aggregation and oxidation of the cyclic heptapeptide. I aliquot only what a single research session requires and keep the parent stock thermally undisturbed.

Reconstitution should use bacteriostatic water (0.9% benzyl alcohol) rather than plain sterile water whenever the working solution will be drawn from over multiple sessions. The benzyl alcohol suppresses microbial growth across the in-use period. For a 10 mg payload reconstituted with 2 mL of diluent, the resulting concentration is 5 mg/mL, or 500 µg per 0.1 mL on an insulin syringe scale. This simplifies volumetric calculations for receptor-binding or in vitro signalling models referenced against the Wikberg melanocortin profile.

MT-II is light-sensitive in solution. Amber vials, foil wrapping, or storage inside an opaque container limits photodegradation of the Trp and Phe residues. The pen format reduces open-air handling steps compared with loose-vial reconstitution, the same logistical rationale that applies to the Body Pharm Tesamorelin 32 Pen. Researchers cross-comparing melanocortin agonists with PT-141 should standardise diluent, concentration, and storage temperature across both peptides to keep variables controlled.

MT-II vs Related Melanocortin Peptides: Quick Comparison

MT-II is a non-selective melanocortin agonist active at MC1R, MC3R, MC4R and MC5R. PT-141 (bremelanotide) is a direct metabolite of MT-II with a functionally MC4R-dominant profile. Afamelanotide (Melanotan I, Scenesse) is an α-MSH analogue with MC1R-leaning activity that is EMA-approved as an orphan medicinal product for erythropoietic protoporphyria. The three peptides share a melanocortin backbone but diverge sharply in receptor bias, regulatory status, and the formats available to UAE researchers.

Attribute	MT-II	Afamelanotide (MT-I / Scenesse)	PT-141 (Bremelanotide)
Receptor selectivity	Pan-MC1R/3R/4R/5R agonist	α-MSH analogue, MC1R-leaning	MC4R-dominant metabolite of MT-II
Primary research application	Melanogenesis and melanocortin signalling models	Phototoxicity prevention in EPP (clinical)	MC4R-mediated CNS signalling research
Approval status	Not EMA-approved; research peptide only	EMA marketing authorisation 2014, renewed through 2023–2024	Not EMA-approved in this research context
UAE registration (MOHAP)	Not listed as registered medicine	Not UAE-registered as of Q1 2026	Not listed as registered medicine
Format on JCSG UAE	Body Pharm Melanotan II 20 Pen, lyophilised vials	Not stocked	Not stocked (research comparator only)

For receptor-binding work, if MC4R isolation is the goal, PT-141 is the cleaner tool given its MC4R dominance. If pigmentation pathways via MC1R are the endpoint, afamelanotide has the historical clinical dataset behind it but is inaccessible outside EMA channels. MT-II remains the broad-spectrum reference compound, and the pen format mirrors the logistical pattern of the Body Pharm Tesamorelin 32 Pen within the same supplier range.

Frequently Asked Questions: Melanotan II UAE